Clinical predictors of long-term efficacy of first-line pembrolizumab monotherapy in non-small cell lung cancer (NSCLC): an interim analysis of real-world data

被引：0

作者：

Younan, Helen-Cara ^{[1
]}

Zhang, Shuai ^{[2
]}

Monroy, Maria ^{[3
]}

Almusarhed, Manar ^{[4
]}

Julve, Max ^{[5
]}

Roy, Debashree ^{[4
]}

Toghey, Sopozme ^{[2
]}

Ahmed, Zartaj ^{[2
]}

Slater, Stephanie ^{[5
]}

Altharwane, Shaymaa ^{[4
]}

Giorgiou, Alex ^{[3
]}

Ghosh, Sharmistha ^{[3
]}

Gennatas, Spyridon ^{[3
]}

Karapanagiotou, Eleni ^{[3
]}

Montes, Ana ^{[3
]}

Pintus, Elias ^{[3
]}

Spicer, James ^{[3
]}

Shah, Riyaz ^{[2
]}

Ahmed, Samreen ^{[4
]}

Newsom-Davis, Tom ^{[5
]}

Mohammed, Waleed ^{[1
]}

Power, Danielle ^{[1
]}

Evans, Joanne ^{[1
]}

Hatcher, Olivia ^{[1
]}

Lakhani, Amish ^{[1
]}

Samani, Amit ^{[1
]}

Josephs, Debra ^{[3
]}

机构：

[1] Imperial Coll Healthcare NHS Trust, London, England

[2] Maidstone & Tunbridge Wells NHS Trust, Tunbridge Wells, Kent, England

[3] Guys & St Thomas NHS Fdn Trust, London, England

[4] Univ Hosp Leicester NHS Trust, Leicester, Leics, England

[5] Chelsea & Westminster Hosp NHS Fdn Trust, London, England

来源：

LUNG CANCER | 2022年 / 165卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：S32 / S32

页数：1

共 50 条

[21] Safety and Efficacy of First-Line Pembrolizumab in Black Patients with Metastatic Non-Small Cell Lung Cancer
Peravali, Monica
Ahn, Jaeil
Chen, Kevin
Rao, Suman
Veytsman, Irina
Liu, Stephen V.
Kim, Chul
ONCOLOGIST, 2021, 26 (08): : 694 - 700
[22] First-line pembrolizumab monotherapy in metastatic PD-L1 positive non-small cell lung cancer: A real-world analysis of time on treatment in US community oncology practices
Velcheti, V.
Chandwani, S.
Chen, X.
Pietanza, M. C.
Burke, T.
ANNALS OF ONCOLOGY, 2018, 29 : 18 - 18
[23] Real-World Costs of Adverse Events in First-Line Treatment of Metastatic Non-Small Cell Lung Cancer
Engel-Nitz, Nicole M.
Johnson, Michael P.
Bunner, Scott H.
Ryan, Kellie J.
JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2020, 26 (06): : 729 - 740
[24] Cancer cachexia as a determinant of efficacy of first-line pembrolizumab in patients with advanced non-small cell lung cancer
Fujii, Hironori
Araki, Ayumu
Iihara, Hirotoshi
Kaito, Daizo
Hirose, Chiemi
Kinomura, Motohiko
Yamazaki, Mizuki
Endo, Junki
Inui, Toshiya
Yanase, Komei
Sasaki, Yuka
Gomyo, Takenobu
Sakai, Chizuru
Kawae, Daisuke
Kitamura, Yu
Fukui, Masachika
Kobayashi, Ryo
Ohno, Yasushi
Suzuki, Akio
MOLECULAR AND CLINICAL ONCOLOGY, 2022, 16 (04)
[25] Afatinib as First-Line Treatment in Elderly Patients with EGFR-Mutant Non-Small Cell Lung Cancer: Real-World Data Analysis
Chen, Yen-Ting
Yen, Chia-Te
Wu, Wen-Jui
Yang, Sheng-Hsiung
INTERNATIONAL JOURNAL OF GERONTOLOGY, 2022, 16 (03) : 266 - 270
[26] THE REAL-WORLD EFFICACY OF FIRST-LINE TYROSINE KINASE INHIBITORS IN ASIAN PATIENTS WITH EGFR MUTATION NON-SMALL CELL LUNG CANCER
Su, Vincent Yi-Fong
Yang, Kuang-Yao
Chen, Yuh-Min
RESPIROLOGY, 2018, 23 : 21 - 22
[27] Long-Term Responders to first-line single agent immunotherapy in advanced Non-Small Cell Lung Cancer. Real-world evidence from The Christie.
Rodriguez, Gomez-Randulfe Martin Igor
Gomes, Fabio
Blackhall, Fiona
Hughes, Sarah
Cove-Smith, Laura
Taylor, Paul
Summers, Yvonne
Pearce, Mark
Califano, Raffaele
LUNG CANCER, 2024, 190
[28] An algorithmic approach to deriving line of therapy in a real-world data set for non-small cell lung cancer (NSCLC).
Shadra, Chhaya
Chen, James Lin
Cho-Phan, Cheryl D.
Ghosh, Aradhana
Hirsch, Jonathan
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[29] Long-Term Survival of Patients With Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor Monotherapy in Real-World Settings
Yoneda, Taro
Sone, Takashi
Koba, Hayato
Shibata, Kazuhiko
Suzuki, Junya
Tani, Mayuko
Nishitsuji, Masaru
Nishi, Koichi
Kobayashi, Takafumi
Shirasaki, Hiroki
Araya, Tomoyuki
Kita, Toshiyuki
Kase, Kazumasa
Yamamura, Kenta
Terada, Nanao
Nishikawa, Shingo
Tambo, Yuichi
Kimura, Hideharu
Kasahara, Kazuo
CLINICAL LUNG CANCER, 2022, 23 (06) : 467 - 476
[30] COST-EFFECTIVENESS OF ATEZOLIZUMAB MONOTHERAPY VERSUS PEMBROLIZUMAB MONOTHERAPY FOR FIRST-LINE TREATMENT OF METASTATIC NON-SMALL CELL LUNG CANCER
Lin, C. W.
Rosettie, K.
Bilir, S. P.
Celik, H.
Abogunrin, S.
Ogale, S.
VALUE IN HEALTH, 2021, 24 : S37 - S37

← 1 2 3 4 5 →